Compare · MLAB vs TMO
MLAB vs TMO
Side-by-side comparison of Mesa Laboratories Inc. (MLAB) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MLAB and TMO operate in Industrial Machinery/Components (Industrials), so they compete in similar markets.
- TMO is the larger of the two at $183.03B, about 324.7x MLAB ($563.6M).
- Over the past year, MLAB is up 4.5% and TMO is up 24.5% - TMO leads by 20.0 points.
- TMO has been more active in the news (17 items in the past 4 weeks vs 3 for MLAB).
- TMO has more recent analyst coverage (25 ratings vs 3 for MLAB).
- Company
- Mesa Laboratories Inc.
- Thermo Fisher Scientific Inc
- Price
- $104.66+3.04%
- $493.55+0.20%
- Market cap
- $563.6M
- $183.03B
- 1M return
- +4.35%
- +2.96%
- 1Y return
- +4.52%
- +24.50%
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 3
- 17
- Recent ratings
- 3
- 25
Mesa Laboratories Inc.
Mesa Laboratories, Inc. designs, manufactures, and markets quality control instruments and disposable products in the United States, Europe, Asia, North America, and internationally. The company's Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. This segment also provides testing and laboratory services primarily to the dental industry. The company's Instruments segment designs, manufactures, and markets quality control hardware and disposable products used in the healthcare, pharmaceutical, food and beverage, medical device, industrial hygiene, and environmental air sampling industries. This segment's products include dialysate meters and calibration solutions, data loggers, gas flow calibration and air sampling equipment, and torque testing systems. The company's Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. This segment's solutions include protein analysis comprising analysis equipment, CDs, kits, and buffers; and peptide synthesizers that enables to automate chemically synthesized peptides that are used in the creation of peptide therapies, biomaterials, cosmetics, and general research. The company's Continuous Monitoring segment designs, develops, and markets systems, which are used to monitor various environmental parameters, such as temperature, humidity, and differential pressure to ensure that critical storage and processing conditions are maintained in hospitals, pharmaceutical and medical device manufacturers, blood banks, pharmacies, and laboratory environments. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest MLAB
- Mesa Laboratories Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Mesa Labs Announces Fourth Quarter and Fiscal Year 2026 Results
- Amendment: SEC Form 4 filed by President and CEO Kadia Siddhartha
- Mesa Laboratories, Inc. to Announce Fourth Quarter and Full Fiscal Year Results on May 27, 2026
- SEC Form 4 filed by President and CEO Kadia Siddhartha
- SEC Form 3 filed by new insider Kadia Siddhartha
- MESA LABS DECLARES QUARTERLY DIVIDEND
- SEC Form 4 filed by Owens Gary M
- Amendment: SEC Form SCHEDULE 13G/A filed by Mesa Laboratories Inc.
- Mesa Laboratories Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
Latest TMO
- SEC Form SD filed by Thermo Fisher Scientific Inc
- Thermo Fisher Scientific Unveils Next-generation Innovations at ASMS 2026 to Accelerate the Path from Drug Discovery to New Therapies
- Thermo Fisher Scientific Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Weisler Dion J covered exercise/tax liability with 80 shares and was granted 499 shares, increasing direct ownership by 8% to 5,446 units (SEC Form 4)
- Director Sperling Scott M was granted 499 shares, increasing direct ownership by 0.72% to 69,479 units (SEC Form 4)
- Director Spar Debora L was granted 499 shares, increasing direct ownership by 24% to 2,610 units (SEC Form 4)
- Director Lynch Karen S was granted 499 shares, increasing direct ownership by 76% to 1,159 units (SEC Form 4)
- Director Keith R. Alexandra was granted 499 shares, increasing direct ownership by 24% to 2,602 units (SEC Form 4)
- Director Johnson Jennifer M was granted 499 shares, increasing direct ownership by 55% to 1,403 units (SEC Form 4)
- Director Jacks Tyler was granted 499 shares, increasing direct ownership by 6% to 9,462 units (SEC Form 4)